8-Chloro-11-(1-((4-nitrophenyl)sulfonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并环庚烷吡啶
• 英文名称: 8-Chloro-11-(1-((4-nitrophenyl)sulfonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine
• 英文别名: 13-Chloro-2-[1-(4-nitrophenyl)sulfonylpiperidin-4-ylidene]-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
• 化学式: C₂₅H₂₂ClN₃O₄S
• 分子量: 495.986
• InChiKey: KKKZIJAWZWHALO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  34
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-Chloro-11-(1-((4-nitrophenyl)sulfonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine 在 盐酸 、 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 以88%的产率得到4-((4-(8-Chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)-ylidene)piperidin-1-yl)sulfonyl)aniline
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Substituted Desloratadines as Potent Arginine Vasopressin V2 Receptor Antagonists

  摘要：

  合成了21种非肽类取代的去氯雷他定类化合物，这些化合物是通过连续的酰化、还原和酰化反应从去氯雷他定合成的，作为新型的抗阿根廷加压素受体拮抗剂。其结构通过1H-NMR和高分辨质谱（HRMS）进行了表征，生物活性通过体外和体内研究进行了评估。体外结合测定和cAMP积累实验表明，这些化合物是有效的选择性V2受体拮抗剂。其中，化合物1n、1t和1v表现出对V2受体的高亲和力和良好的选择性。体内利尿实验表明，1t具有显著的利尿活性。总之，1t是一个强效的新型AVP V2受体拮抗剂候选物。

  DOI：

  10.3390/molecules19022694
• 作为产物：
  描述：

  氯雷他定 在 盐酸 、 potassium carbonate 作用下， 以 水 、 甲苯 为溶剂， 生成 8-Chloro-11-(1-((4-nitrophenyl)sulfonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine
  参考文献：
  名称：

  Novel tricyclic aminoacetyl and sulfonamide inhibitors of Ras farnesyl protein transferase

  摘要：

  Novel tricyclic FPT inhibitors with submicromolar FPT activity are described. Greatly enhanced FPT activity is realized with phthaloyl derivatized amino compound 2k, which showed FPT inhibitory activity of IC50 = 0.66 mu M. Sulfonamides 5g and 50 were also found to be potent FPT inhibitor. SAR resulting from a variety of tricyclic amino acids and sulfonamide derivatives is discussed. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00558-6

文献信息

• Synthesis of Isomeric 3-Piperidinyl and 3-Pyrrolidinyl Benzo[5,6]cyclohepta[1,2-b]pyridines: Sulfonamido Derivatives as Inhibitors of Ras Prenylation
  作者：Joseph Kelly、Ronald Wolin、Michael Connolly、Adriano Afonso、Linda James、Paul Kirshmeier、W.Robert Bishop、Andrew T. McPhail

  DOI：10.1016/s0968-0896(98)00026-1

  日期：1998.6

  Blocking farnesylation of oncogenic Ras proteins is a mechanism based therapeutic approach that is of current interest for the development of antitumor agents to treat ras associated tumors. As part of a SAR study on the lead farnesyl protein transferase (FPT) inhibitor I, we report here the synthesis of novel geometric isomers II and III and the FPT inhibition activity of their N-acyl and N-sulfonamido

  阻断致癌性Ras蛋白的法尼基化是一种基于机制的治疗方法，目前对于开发治疗ras相关肿瘤的抗肿瘤药物具有重要意义。作为对法呢基铅蛋白转移酶（FPT）抑制剂I的SAR研究的一部分，我们在这里报告了新型几何异构体II和III的合成及其N-酰基和N-磺酰胺基衍生物15-65的FPT抑制活性。N-酰基衍生物的活性显着低于铅抑制剂I，从而表明I中N-酰基的空间位置对于化合物与FPT的结合至关重要。与I相反，N-磺酰胺基-II系列是非巯基非肽类化合物的新型先导，它们是FPT / GGPT双重抑制剂。根据最近有关N-和K-Ras异戊烯化的报道，
• 双磺酰胺类化合物及其制备方法和用途
  申请人：天津药物研究院

  公开号：CN103936713B

  公开（公告）日：2016-01-20

  本发明涉及一类双磺酰胺类化合物及其制备方法和用途。具体地，涉及一类具有式I结构的双磺酰胺类化合物及其药学上可接受的盐及其制备方法，式I结构的双磺酰胺类化合物及其药学上可接受的盐作为活性有效成分的药物组合物及其在预防或治疗与精氨酸加压素V1a受体、精氨酸加压素V1b受体、精氨酸加压素V2受体、交感神经系统或肾素-血管紧张素-醛固酮系统相关的疾病中的用途。
• Synthesis and biological evaluation of novel derivatives of desloratadine
  作者：Shuai Mu、Xiao-Shuai Xie、Duan Niu、Da-Shuai Zhang、Deng-Ke Liu、Chang-Xiao Liu

  DOI：10.1016/j.cclet.2013.03.041

  日期：2013.6

  Series of novel derivatives of desloratadine designed as arginine vasopressin receptor antagonists were synthesized and structurally characterized by melting points, H-1 NMR and HRMS. Their in vivo diuretic activities were evaluated on rats, and several target compounds showed promising diuretic results, especially compounds 8,18,27 and 31. Further in vitro bonding assay and cAMP assay showed that these compounds had a higher affinity to vasopressin V2 receptor than Via receptor. Our studies indicated that desloratadine may be an active substructure for novel arginine vasopressin receptor antagonist development. (C) 2013 Chang-Xiao Liu. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
• Novel tricyclic aminoacetyl and sulfonamide inhibitors of Ras farnesyl protein transferase
  作者：F.George Njoroge、Bancha Vibulbhan、Carmen S. Alvarez、W.Robert Bishop、Joanne Petrin、Ronald J. Doll、V. Girijavallabhan、Ashit K. Ganguly

  DOI：10.1016/s0960-894x(96)00558-6

  日期：1996.12

  Novel tricyclic FPT inhibitors with submicromolar FPT activity are described. Greatly enhanced FPT activity is realized with phthaloyl derivatized amino compound 2k, which showed FPT inhibitory activity of IC50 = 0.66 mu M. Sulfonamides 5g and 50 were also found to be potent FPT inhibitor. SAR resulting from a variety of tricyclic amino acids and sulfonamide derivatives is discussed. Copyright (C) 1996 Elsevier Science Ltd
• Synthesis and Biological Evaluation of Substituted Desloratadines as Potent Arginine Vasopressin V2 Receptor Antagonists
  作者：Shuai Mu、Ying Liu、Min Gong、Deng-Ke Liu、Chang-Xiao Liu

  DOI：10.3390/molecules19022694

  日期：——

  Twenty-one non-peptide substituted desloratadine class compounds were synthesized as novel arginine vasopressin receptor antagonists from desloratadine via successive acylation, reduction and acylation reactions. Their structures were characterized by 1H-NMR and HRMS, their biological activity was evaluated by in vitro and in vivo studies. The in vitro binding assay and cAMP accumulation assay indicated that these compounds are potent selective V2 receptor antagonists. Among them compounds 1n, 1t and 1v exhibited both high affinity and promising selectivity for V2 receptors. The in vivo diuretic assay demonstrated that 1t presented remarkable diuretic activity. In conclusion, 1t is a potent novel AVP V2 receptor antagonist candidate.

  合成了21种非肽类取代的去氯雷他定类化合物，这些化合物是通过连续的酰化、还原和酰化反应从去氯雷他定合成的，作为新型的抗阿根廷加压素受体拮抗剂。其结构通过1H-NMR和高分辨质谱（HRMS）进行了表征，生物活性通过体外和体内研究进行了评估。体外结合测定和cAMP积累实验表明，这些化合物是有效的选择性V2受体拮抗剂。其中，化合物1n、1t和1v表现出对V2受体的高亲和力和良好的选择性。体内利尿实验表明，1t具有显著的利尿活性。总之，1t是一个强效的新型AVP V2受体拮抗剂候选物。